Study explores use of imaging mass cytometry to identify therapeutic targets in kidney cancer
Researchers may be able to use imaging mass cytometry to capture and classify the tumor-immune evasion cell networks in clear cell renal cell carcinoma.
Related Articles
Dr. Shore on what he’s most looking forward to at AUA 2024
Neal D. Shore, MD, shares what he’s most looking forward to at this year’s American Urological Association Annual Meeting.
Your New Tower
UroViu’s portable and versatile disposable cystoscopy platform delivers consistent performance, on par with reusable scopes, advancing clinical care, and limiting disposable waste. The benefit of…
Expert discusses novel approach to ctDNA detection in MIBC
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have…
TRANSFORM trial to evaluate screening methods in prostate cancer
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Innovation fund to bolster adoption of prostate cancer test
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
Medicare’s G2211 and thoughts on how to best use it in urology
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…
Study identifies method to reduce extended-spectrum antibiotic use for UTI
“Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the…
Gem-doce and BCG yield similar outcomes for upper tract urothelial cell carcinoma
“Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel…
Study progresses of NK cell therapy in mCRPC
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Conference
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.